(GERN) Geron - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US3741631036
Telomerase Inhibitor, Myelodysplastic Syndromes, Anemia
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 66.6% |
| Value at Risk 5%th | 101% |
| Relative Tail Risk | -8.25% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.29 |
| Alpha | -82.70 |
| CAGR/Max DD | -0.22 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.502 |
| Beta | 1.087 |
| Beta Downside | 0.870 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.98% |
| Mean DD | 36.96% |
| Median DD | 35.64% |
Description: GERN Geron November 18, 2025
Geron Corporation (NASDAQ:GERN) is a commercial-stage biopharma focused on oncology, best known for its telomerase inhibitor RYTELO, which is approved for adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who are transfusion-dependent. The company, founded in 1990 and based in Foster City, California, trades as a common stock within the U.S. Biotechnology sub-industry.
Key metrics as of the latest filing show a market capitalization of roughly $1.2 billion, cash and cash equivalents of about $180 million, and an annualized cash burn rate near $120 million, implying ~1.5 years of runway without additional financing. The telomerase inhibition mechanism aligns with broader sector trends that reward differentiated molecular targets, especially as the aging U.S. population drives increasing demand for MDS and other hematologic therapies. Geron’s pipeline also includes a pre-clinical telomerase-based candidate for solid tumors, which could diversify revenue beyond RYTELO if successful.
If you’re looking to deepen your analysis, ValueRay’s platform offers granular, real-time data on Geron’s financial health and peer benchmarks that can help you assess the sustainability of its cash position and the market’s pricing of its telomerase strategy.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-80.0m TTM) > 0 and > 6% of Revenue (6% = 11.0m TTM) |
| FCFTA -0.23 (>2.0%) and ΔFCFTA 25.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 237.0% (prev 882.4%; Δ -645.4pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.23 (>3.0%) and CFO -132.9m <= Net Income -80.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (667.1m) change vs 12m ago 0.75% (target <= -2.0% for YES) |
| Gross Margin 86.21% (prev 96.65%; Δ -10.44pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.23% (prev 6.63%; Δ 29.61pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.35 (EBITDA TTM -44.9m / Interest Expense TTM 34.1m) >= 6 (WARN >= 3) |
Altman Z'' -12.10
| (A) 0.77 = (Total Current Assets 522.3m - Total Current Liabilities 87.7m) / Total Assets 567.4m |
| (B) -3.22 = Retained Earnings (Balance) -1.83b / Total Assets 567.4m |
| warn (B) unusual magnitude: -3.22 — check mapping/units |
| (C) -0.09 = EBIT TTM -45.9m / Avg Total Assets 506.2m |
| (D) -5.73 = Book Value of Equity -1.83b / Total Liabilities 318.7m |
| Total Rating: -12.10 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.25
| 1. Piotroski 0.50pt |
| 2. FCF Yield -29.11% |
| 3. FCF Margin -72.42% |
| 4. Debt/Equity 0.49 |
| 5. Debt/Ebitda -0.98 |
| 6. ROIC - WACC (= -18.85)% |
| 7. RoE -30.28% |
| 8. Rev. Trend 73.62% |
| 9. EPS Trend 76.86% |
What is the price of GERN shares?
As of December 08, 2025, the stock is trading at USD 1.31 with a total of 4,671,414 shares traded.
Over the past week, the price has changed by +10.08%, over one month by +22.43%, over three months by -4.38% and over the past year by -67.09%.
Over the past week, the price has changed by +10.08%, over one month by +22.43%, over three months by -4.38% and over the past year by -67.09%.
Is GERN a buy, sell or hold?
Geron has received a consensus analysts rating of 4.11.
Therefore, it is recommended to buy GERN.
- Strong Buy: 4
- Buy: 2
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GERN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 3.3 | 154.2% |
| Analysts Target Price | 3.3 | 154.2% |
| ValueRay Target Price | 1.1 | -19.1% |
GERN Fundamental Data Overview November 25, 2025
Market Cap USD = 715.0m (715.0m USD * 1.0 USD.USD)
P/S = 3.8983
P/B = 2.8875
P/EG = -2.38
Beta = 0.561
Revenue TTM = 183.4m USD
EBIT TTM = -45.9m USD
EBITDA TTM = -44.9m USD
Long Term Debt = 119.3m USD (from longTermDebt, last quarter)
Short Term Debt = 994.0k USD (from shortTermDebt, last quarter)
Debt = 121.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 43.8m USD (from netDebt column, last quarter)
Enterprise Value = 456.3m USD (715.0m + Debt 121.9m - CCE 380.5m)
Interest Coverage Ratio = -1.35 (Ebit TTM -45.9m / Interest Expense TTM 34.1m)
FCF Yield = -29.11% (FCF TTM -132.8m / Enterprise Value 456.3m)
FCF Margin = -72.42% (FCF TTM -132.8m / Revenue TTM 183.4m)
Net Margin = -43.61% (Net Income TTM -80.0m / Revenue TTM 183.4m)
Gross Margin = 86.21% ((Revenue TTM 183.4m - Cost of Revenue TTM 25.3m) / Revenue TTM)
Gross Margin QoQ = 53.18% (prev 97.57%)
Tobins Q-Ratio = 0.80 (Enterprise Value 456.3m / Total Assets 567.4m)
Interest Expense / Debt = 7.09% (Interest Expense 8.64m / Debt 121.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -36.3m (EBIT -45.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.96 (Total Current Assets 522.3m / Total Current Liabilities 87.7m)
Debt / Equity = 0.49 (Debt 121.9m / totalStockholderEquity, last quarter 248.7m)
Debt / EBITDA = -0.98 (negative EBITDA) (Net Debt 43.8m / EBITDA -44.9m)
Debt / FCF = -0.33 (negative FCF - burning cash) (Net Debt 43.8m / FCF TTM -132.8m)
Total Stockholder Equity = 264.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.10% (Net Income -80.0m / Total Assets 567.4m)
RoE = -30.28% (Net Income TTM -80.0m / Total Stockholder Equity 264.2m)
RoCE = -11.98% (EBIT -45.9m / Capital Employed (Equity 264.2m + L.T.Debt 119.3m))
RoIC = -9.47% (negative operating profit) (NOPAT -36.3m / Invested Capital 383.1m)
WACC = 9.38% (E(715.0m)/V(836.9m) * Re(10.02%) + D(121.9m)/V(836.9m) * Rd(7.09%) * (1-Tc(0.21)))
Discount Rate = 10.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.89%
Fair Price DCF = unknown (Cash Flow -132.8m)
EPS Correlation: 76.86 | EPS CAGR: 80.91% | SUE: -0.36 | # QB: 0
Revenue Correlation: 73.62 | Revenue CAGR: 176.6% | SUE: -1.24 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.03 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.07 | Chg30d=-0.049 | Revisions Net=-2 | Growth EPS=+37.5% | Growth Revenue=+39.4%
P/S = 3.8983
P/B = 2.8875
P/EG = -2.38
Beta = 0.561
Revenue TTM = 183.4m USD
EBIT TTM = -45.9m USD
EBITDA TTM = -44.9m USD
Long Term Debt = 119.3m USD (from longTermDebt, last quarter)
Short Term Debt = 994.0k USD (from shortTermDebt, last quarter)
Debt = 121.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 43.8m USD (from netDebt column, last quarter)
Enterprise Value = 456.3m USD (715.0m + Debt 121.9m - CCE 380.5m)
Interest Coverage Ratio = -1.35 (Ebit TTM -45.9m / Interest Expense TTM 34.1m)
FCF Yield = -29.11% (FCF TTM -132.8m / Enterprise Value 456.3m)
FCF Margin = -72.42% (FCF TTM -132.8m / Revenue TTM 183.4m)
Net Margin = -43.61% (Net Income TTM -80.0m / Revenue TTM 183.4m)
Gross Margin = 86.21% ((Revenue TTM 183.4m - Cost of Revenue TTM 25.3m) / Revenue TTM)
Gross Margin QoQ = 53.18% (prev 97.57%)
Tobins Q-Ratio = 0.80 (Enterprise Value 456.3m / Total Assets 567.4m)
Interest Expense / Debt = 7.09% (Interest Expense 8.64m / Debt 121.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -36.3m (EBIT -45.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.96 (Total Current Assets 522.3m / Total Current Liabilities 87.7m)
Debt / Equity = 0.49 (Debt 121.9m / totalStockholderEquity, last quarter 248.7m)
Debt / EBITDA = -0.98 (negative EBITDA) (Net Debt 43.8m / EBITDA -44.9m)
Debt / FCF = -0.33 (negative FCF - burning cash) (Net Debt 43.8m / FCF TTM -132.8m)
Total Stockholder Equity = 264.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.10% (Net Income -80.0m / Total Assets 567.4m)
RoE = -30.28% (Net Income TTM -80.0m / Total Stockholder Equity 264.2m)
RoCE = -11.98% (EBIT -45.9m / Capital Employed (Equity 264.2m + L.T.Debt 119.3m))
RoIC = -9.47% (negative operating profit) (NOPAT -36.3m / Invested Capital 383.1m)
WACC = 9.38% (E(715.0m)/V(836.9m) * Re(10.02%) + D(121.9m)/V(836.9m) * Rd(7.09%) * (1-Tc(0.21)))
Discount Rate = 10.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.89%
Fair Price DCF = unknown (Cash Flow -132.8m)
EPS Correlation: 76.86 | EPS CAGR: 80.91% | SUE: -0.36 | # QB: 0
Revenue Correlation: 73.62 | Revenue CAGR: 176.6% | SUE: -1.24 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.03 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.07 | Chg30d=-0.049 | Revisions Net=-2 | Growth EPS=+37.5% | Growth Revenue=+39.4%
Additional Sources for GERN Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle